Professor Lyu Aiping is Chair Professor & Dean of School of Chinese Medicine, Hong Kong Baptist University, Director of Institute for Advancing Translational Medicine in Bone & Joint Diseases (TMBJ) of HKBU, Director of Institute of Integrated Bioinformedicine & Translational Science (IBTS) of HKBU, Chair Professor in China Academy of Chinese Medical Sciences (CACMS) and Recipient of the Distinguished Young Scholar in National Science Foundation of China (NSFC) in 2007. He is the member of the 11th and 12th the National Committee of the Chinese People's Consultative Conference (CPPCC), and the member of the 11 th Beijing Committee of the Chinese People's Consultative Conference. Prof. Lyu is also the member of Hong Kong Chinese Medicine Development Committee, the member of Hong Kong Chinese Medicine Administration Committee, the member of Biology and Medicine Panel in Hong Kong Research Grant Committee (RGC).
Being a renowned expert and academic in the field, Prof Lyu has been appointed as Head & Spokesperson of the China Delegation, International Organization for Standardization Technical Committee on TCM (ISO/TC249) since 2009. Besides, he also currently serves as Member of Medical Advisory Committee of National Natural Science Foundation of China (NSFC), Member of Chinese Pharmacopoeia Commission and Vice-Chairman, Terminology of Traditional Chinese Medicine Sub-Committee, China National Committee for Terms in Sciences and Technologies (CNCTST). Also he is the director of Chinese Medicine Standardization Office in State Administration of Traditional Chinese Medicine (SATCM), and the director of Chinese Medicine Standard Research Center in CACMS.
He obtained his bachelor degree from Jiangxi University of Traditional Chinese Medicine in 1983, and further obtained his master's and Ph.D. degrees from China Academy of Traditional Chinese Medicine (now called the China Academy of Chinese Medical Sciences, CACMS). From 2006 to 2012, he was the Director of Institute of Basic Research in Clinical Medicine, and the Director of Institute of Basic Theory of CACMS from 1999 to 2002. In 2002-2006, Prof Lyu was appointed as General Director, Jiangxi Herbfine Hi-tech Co. Ltd (National Pharmaceutical Engineering Centre for Solid Preparation), one of four centres in China in the field of Traditional Chinese Medicine industry.
His research interests mainly focus on the translational research in Chinese medicine, including pharmacological and clinical evaluation on rheumatoid arthritis with TCM pattern diagnosis and interventions, and development of new drugs based on Chinese medicines. Also he is actively involving the research on the standardization of Chinese medicine and strategic plan research for Chinese medicine development in China.
Prof Lyu has published more than 30 books and over 500 articles, including 200 articles in SCI journals such as Nature Medicine, Nature Communication, Biomaterials, Briefings in Bioinformatics, Clinical Pharmacology and Therapeutics, Scientific Reports, Journal of Proteomic Research. With his leadership, 3 standards related to Chinese medicine have been issued. One is the General Guidelines for Clinical Practice guideline in Chinese Medicine issued by Chinese Association of Chinese Medical Sciences, and other 2 related to Chinese medicine Coding Systems issued as national standards. As the head or deputy head, he led a team and completed several strategic research reports, including Health China 2020, the 13th Five Year Planning on Chinese Medicine Research in NSFC, strategic planning for Chinese medicine standardization (both domestic and internal). Over the years, he obtained more than 60 patents from his research activities.
He was invited to serve as Visiting Scholar in a number of institutions including Lund University in Sweden, Ohio State University in the United States, Hong Kong Polytechnic University and Hong Kong University of Science and Technology. Based on his outstanding research achievement, Prof Lyu was invited as guest speakers in various international academic conferences.